Design of idiopathic pulmonary fibrosis clinical trials in the era of approved therapies

Luca Richeldi, Robert J. Kaner, Ednan K. Bajwa, Moustapha El-Amine, Eduard Gorina, Renu Gupta, Howard M. Lazarus, Tracy R. Luckhardt, Majd Mouded, Kaity Posada, John Stauffer, Ahmet Tutuncu, Fernando J. Martinez

Risultato della ricerca: Contributo in rivistaArticolo in rivista

3 Citazioni (Scopus)

Abstract

Idiopathic pulmonary fibrosis (IPF) is a progressivediseasewithamediansurvivalof 3–5 years (1, 2). The approval of nintedanib and pirfenidone by regulatory agencies worldwide has dramatically altered the landscape for testing new drugs for IPF treatment. These drugs slowed the progression of the FVC decline observed in IPF cohorts in phase III randomized, double-blind, placebo-controlled trials (3, 4).
Lingua originaleEnglish
pagine (da-a)133-139
Numero di pagine7
RivistaAmerican Journal of Respiratory and Critical Care Medicine
Volume200
DOI
Stato di pubblicazionePubblicato - 2019

Keywords

  • Anti-Inflammatory Agents, Non-Steroidal
  • Clinical Trials as Topic
  • Drug Approval
  • Drug Development
  • Drug Interactions
  • Drug Therapy, Combination
  • Humans
  • Idiopathic Pulmonary Fibrosis
  • Indoles
  • Patient Outcome Assessment
  • Protein Kinase Inhibitors
  • Pyridones
  • Quality of Life
  • Standard of Care
  • Vital Capacity
  • Walk Test

Fingerprint

Entra nei temi di ricerca di 'Design of idiopathic pulmonary fibrosis clinical trials in the era of approved therapies'. Insieme formano una fingerprint unica.

Cita questo